Company Information
Industry 制造业
Company Introduction 浙江海翔药业股份有限公司主要从事生产化学合成医药原料药和精细化学品(包括中间体).公司生产的原料药包括人药部分和兽药部分,主要产品有抗生素类、降糖类、消炎镇痛类、驱虫类药物,利尿类药物等产品.2005年度,本公司列我国化学原料药企业销售收入100强的第26位,是全国医药工业企业创新能力百强企业之一.是浙江省首批诚信示范企业、浙江省自营出口优秀生产企业、浙江省工商联民营会员百强企业;是国家火炬计划重点高新技术企业、浙江省高新技术企业、台州市绿色企业。
Main Business 特色原料药及医药中间体、仿制药的研发和商业化生产销售,并为全球知名制药企业提供定制研发及生产服务(CMO/CDMO);环保型活性染料及染颜料中间体的研发、生产及销售。
Legal Representative 许国睿
Top Executives
董事长:王扬超
董事:陶红,许国睿,王晓洋,姚冰
独立董事:俞永平,钱建民,梁超
Top 5 Shareholder
Shareholder name Nature Holding Date
浙江东港实业有限公司流通A股32.37%31/03/2024
王云富流通A股7.34%31/03/2024
林穗凯流通A股2.46%31/03/2024
浙江海翔药业股份有限公司-第一期员工持股计划流通A股1.98%31/03/2024
上海呈瑞投资管理有限公司-呈瑞正乾36号私募证券投资基金流通A股1.67%31/03/2024
Company Secretary 王晓洋
Solicitors 浙江天册律师事务所
Auditors 天健会计师事务所(特殊普通合伙)
Tel No 0576-89088166
Fax No 0576-89088128
Website www.hisoar.com
Email stock@hisoar.com;lyb@hisoar.com
Company Address
Register: 浙江省台州市椒江区外沙支路100号
Office: 浙江省台州市椒江区外沙支路100号
Listing Date 26/12/2006
Shares Capital
Shares Capital: 1,618,715,253
Total A Share: 1,618,715,253
Listed A Share: 1,606,986,516
Non-tradable A Share: 11,728,737
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.260
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 3.463
Market Capitalization(RMB) 10.188B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.